M42 Announces Strategic Investment and Partnership with Leading Biotech Juvenescence
Summary
The announcement was made during Abu Dhabi Global Health Week (ADGHW), a year-round always-on platform with a proactive approach centred around preventive, personalised, and holistic care, which is being held from 15 to 17 April at ADNEC, where M42 serves as a Foundational Partner for the second consecutive year.As part of this investment, M42 and Juvenescence will form a strategic partnership to identify and develop a pipeline of AI-enabled therapeutics to extend healthy lifespan and advance the treatment of life-threatening diseases.The strategic partnership and investment underlines M42s commitment to advancing its capabilities in drug discovery and development following the creation of its Integrated Health Solutions and Life Sciences platforms under its new operating structure announced recently. Leveraging M42s deep expertise in genomics, biobanking, and clinical trial infrastructure alongside Juvenescences cutting-edge AI-enabled discovery technology and extensive drug development expertise, this collaboration will drive breakthroughs in life sciences research, enhance disease understanding, and enable fast-tracking of clinical trials.As well as identifying novel drug targets and therapeutics, the partnership will explore collaboration in R&D with leading academic and research organizations globally and support the development of M42s biotechnology strategy in Abu Dhabi. By uniting AI innovation with biotech expertise, were not only advancing the fight against age-related diseases but also building a global ecosystem that empowers prevention, precision, and progressdelivering transformative therapies from Abu Dhabi to the world.Dr. Our work together will enable the creation of a unique pipeline of innovative therapeutics that will have enormous potential to target the underlying causes of age-related disease and improve the healthspan of patients globally.The collaboration will see Juvenescences team of globally recognized scientists and industry leaders with more than 150 years of cumulative experience in drug discovery and development* work with M42 to build its own innovative therapeutics pipeline.By partnering with Juvenescence, M42 is building on its genomics expertise developed in collaboration with the Department of Health Abu Dhabi (DoH) to further drive advancements in disease understanding and precision medicine. Our diverse, AI-enabled medicines pipeline of clinical and near-clinical stage candidates targeting core ageing mechanisms are in development for cognition, cardio-metabolism, immunity and cellular repair.